PHASE I STUDY OF VORINOSTAT IN COMBINATION WITH TEMOZOLOMIDE IN MALIGNANT GLIOMA

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 (from ClinicalTrials.gov网站） 化疗中使用的药物，如伏立诺他和替莫唑胺，以不同的方式阻止肿瘤细胞的生长，要么杀死细胞，要么阻止它们分裂。伏立诺他还可以通过阻断细胞生长所需的一些酶来阻止肿瘤细胞的生长。伏立诺他可能通过使肿瘤细胞对药物更敏感来帮助替莫唑胺更好地发挥作用。vorinostat与替莫唑胺一起使用可能会杀死更多的肿瘤细胞。 这项I期试验正在研究伏立诺他与替莫唑胺联合治疗恶性胶质瘤患者时的副作用和最佳剂量。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. (from ClinicalTrials.gov website) Drugs used in chemotherapy, such as vorinostat and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vorinostat may help temozolomide work better by making tumor cells more sensitive to the drug. Giving vorinostat together with temozolomide may kill more tumor cells. This Phase I trial is studying the side effects and best dose of vorinostat when given together with temozolomide in treating patients with malignant gliomas.